RETA Stock News

SAN FRANCISCO, Feb. 05, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA ) investors with significant losses to submit your losses now . A securities fraud class action has been filed and certain investors may have valuable claims. Class Period: Nov. 9, 2020 - Dec. 8, 2021 Lead Plaintiff Deadline: Feb. 18, 2022 Visit: www.hbsslaw.com/investor-fraud/RETA Contact An Attorney Now: [email protected] 844-916-0895 Reata Pharmaceuticals, Inc. (RETA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading statements about Reata''s Phase 3 (CARDINAL) study of one of its lead product candidates, bardoxolone methyl for treatment of chronic kidney disease caused by Alport syndrome ("AS") and the related new drug application ("NDA"). Specifically, Defendants failed to disclose to investors: (1) that the Full story available on Benzinga.com

Reata Pharmaceuticals (RETA) has initiated a rolling submission of a New Drug Application ((NDA)) to the FDA for omaveloxolone for the treatment of patients with Friedreichs

NEW YORK, Jan. 08, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA ) between November 9, 2020 and December 8, 2021, inclusive (the "Class Period"), of the important February 18, 2022 lead plaintiff deadline. SO WHAT: If you purchased Reata Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Reata Pharmaceuticals class action, go to http://www.rosenlegal.com/cases-register-2230.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 18, 2022 . A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

NEW YORK, Jan. 5, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between November 9, 2020 and

NEW ORLEANS, Dec. 23, 2021 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 18, 2022 to file lead plaintiff applications in a securities class action lawsuit against

(PR-inside.com) SAN DIEGO, CA / ACCESSWIRE / December 23, 2021 / Robbins Geller Rudman & Dowd LLP announces that purchasers of Reata Pharmaceuticals, Inc. (NASDAQ:RETA) securities and/or sellers of Reata Pharmaceuticals put options between November 9, 2020 and December 8, 2021, inclusive (the "Class Period") have until February 18, 2022 to seek appointment as lead plaintiff in Doyle v. Reata Pharmaceuticals, Inc., No. 21-cv-00987. Commenced on December 20, 2021 in the Eastern District of Texas, the Reata Pharmaceuticals class action lawsuit charges Reata Pharmaceuticals and certain of its top executives with violations of the Securities Exchange Act of 1934. If you wish ..

SAN FRANCISCO, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now . A securities fraud class action has been filed and certain investors may have valuable claims.

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between November 9, 2020 and December 8, 2021, inclusive (the Class Period). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 18, 2022. SO WHAT: If you purchased Reata Pharmaceuticals securities

SAN DIEGO, Dec. 22, 2021 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) securities and/or sellers of Reata Pharmaceuticals put options between November 9, 2020 and December 8, 2021, inclusive (the

LOS ANGELES--(BUSINESS WIRE)---- $RETA #RETA--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Reata Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Reata Pharmaceuticals, Inc. (Reata or the Company) (NASDAQ: RETA) in the United States District Court for the Eastern District of Texas on behalf of all persons and entities who purchased or otherwise acquired Reata securities between November 9, 2020 and December 8, 2021, both dates inclusive (the Class Period). Investors have until February 18, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

LOS ANGELES--(BUSINESS WIRE)---- $RETA #RETA--SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Reata Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $RETA #investors--The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Reata Pharmaceuticals, Inc. (RETA) Investors